News Portal

User avatar
TimGDixon
Posts: 1189
Joined: Fri Jun 26, 2020 4:36 am

News Portal

Post by TimGDixon »

This new forum will be where i'll make announcements in the future. Old press releases can be found here: https://therapeuticsolutionsint.com/press-releases/
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy

Understanding Mechanism of Action of Novel Cancer Therapy Previously Used Outside of USA Supports Response to FDA Regarding Currently Pending Investigational New Drug Application


https://www.prnewswire.com/news-release ... 10088.html


OCEANSIDE, Calif., Jan. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs™ cellular immunotherapy.

In a series of experiments, it was demonstrated that StemVacs™ administration resulted in a) regression of established breast cancer in mice; b) that regression was dependent on natural killer cells, and c) that immunity to breast cancer could be transferred by CD4 T cells to naïve mice.

Previously the Company announced positive safety data in 10 patients treated with StemVacs™1. Additionally, the Company has filed an Investigational New Drug Application (IND) which is currently pending based on the Company responding to questions posed by the FDA.

"The current data, which conclusively demonstrates the induction of immunological memory to cancer, as well as the natural killer cell as a mechanism of action, will position us to provide the FDA responses to their questions from our submitted IND," said Dr. James Veltmeyer, Chief Medical Officer of the Company and voted Top Doctor of San Diego. "Given the fact that we have human safety data from outside of the United States, combined with these new mechanistic findings, we are confident in a smooth interaction with the FDA as we get closer to clearing of our IND application."

"It is known that numerous immunotherapies such as Herceptin® are dependent on the ability of natural killer cells to function properly," said Famela Ramos, Vice President of Business Development. "The current data provides a scientific basis for us to collaborate with other immuno-oncology companies to identify and leverage possible synergies with other drugs that work via the natural killer pathway of the innate immune system."

"Therapeutic Solutions International is a 'science-driven' organization," said Timothy Dixon, President and CEO. "Having key opinion leaders such as Drs. Santosh Kesari and Francesco Marincola as advisors allows us to design and execute experiments with the highest level of academic rigor. We believe that the FDA and our scientific and medical peers will appreciate our philosophy."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 StemVacs Cancer Vaccine Shows Safety and May Be Eligible for Right to Try, Therapeutic Solutions Says (immuno-oncologynews.com)

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Enhancement of StemVacs Immune Stimulating Activity Using Neuromodulatory Compound Homotaurine

Company Continues to Optimize Efficacy of Clinical Stage Off the Shelf Dendritic Cell Cancer Immunotherapy


https://www.prnewswire.com/news-release ... 15167.html


OCEANSIDE, Calif., Jan. 26, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent disclosing enhancement of natural killer cell and T cell activity by StemVacs after treatment with homotaurine, a safe blood-brain barrier permeable GABA A-R-specific agonist. The data suggests the possibility that neurologically acting molecules, such as homotaurine, may be an unexplored area for discovery of novel immune modulators.

"It is known that the immune system and the nervous system are the only two systems of the body which possess memory and ability to distinguish between "self" and "non-self". The potent interactions between the nervous system and immune system is the basis of Campbell Neurosciences, our suicide-prevention spin-off" said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of patent. "Through testing a variety of naturally occurring neurologically active molecules, we found that homotaurine increases the immune stimulatory potential of StemVacs. This data is particularly relevant because it supports the development of a new class of immune modulators that are derived from neurology."

"We are excited about homotaurine from a commercialization perspective. This chemical, which was also known as Tramiprosate or Alzhemed, failed in clinical trials for Alzheimer's but was demonstrated to possess an excellent safety profile" said Famela Ramos, Vice President of Business Development for the Company and co-inventor. "What appears paradoxical is that homotaurine actually works as an anti-inflammatory molecule so we would not have expected it to augment activity of StemVacs. This unexpected finding should provide support for rapid issuance of intellectual property."

"As a corporation we never stop on optimizing our products. We believe that our responsibility, to our investors and to cancer patients, is to always optimize and share results as quickly as possible with the community" said Timothy Dixon, President and CEO of the Company and co-inventor. "We are currently exploring means to incorporate these new findings into the clinical development of StemVacs."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma

Ongoing Studies Support Possibility of Nanoparticle Based Natural Killer Cell Activating Immunotherapy



https://www.prnewswire.com/news-release ... 19050.html


OCEANSIDE, Calif., Feb. 1, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company's cellular immunotherapy product StemVacs.

Exosomes are cell derived nanoparticles which have been demonstrated to transmit biological information between cells. Dr. Thomas Ichim, Board Member of the Company, published 16 years ago that exosomes from cancer are capable of suppressing immunity1. Today the Company reported opposite findings: in some situations, immune cell exosomes can suppress cancer.

"The current findings demonstrate that StemVacs derived exosomes can directly stimulate natural killer cells, which in turn, suppress glioma growth" said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "Exosomes in some cases possess advantages to administration of cells in that they are more stable than cells and are capable of superior biodistribution due to their small size."

"As a clinical stage cancer immunotherapy company, experimental validation of our intellectual property is extremely important for accomplishing our goals of entering into licensing and/or co-development relationships with Large Pharma" stated Famela Ramos Vice President of Business Development. "The fact that companies such as Fate Therapeutics and Nantkwest are attracting valuations in the billions of dollars, supports our belief that the field of natural killer therapeutics is highly perceived by the industry".

"We are in the process of developing responses to our last interaction with the FDA regarding StemVacs cell therapy" said Timothy Dixon, President and CEO of the Company. "By leveraging our scientific colleagues and finding that StemVacs exosomes are effective in glioma, we are evaluating the possibility of applying for another Investigational New Drug application using exosomes."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis - ScienceDirect

https://www.sciencedirect.com/science/a ... via%3Dihub

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC

Clinical Stage Biotechnology Company Partners with Community Health Care Innovator

https://www.prnewswire.com/news-release ... 22346.html


ELK CITY, Idaho, Feb. 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announces today the signing of a Master Sales Agreement with Community Shield LLC of Sheridan Wyoming to distribute its science-based nutraceutical line of products.

Products to be included in the Master Sales Agreement currently consists of QuadraMune™, NanoStilbene™, NeuroStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol®. Future products will be added to Master List as commercialized and provide same levels of discount.

"Execution of this sales agreement by our new Vice President of Business development Famela Ramos, is a significant milestone for us. Community Shield LLC is a company focused on developing innovative ways to deliver optimum health care to specific communities based on science and not opinions or politics, makes CSL an ideal partner," said Timothy Dixon, President and CEO of TSOI. "Since our Company is laser focused on operating as an 'innovation factory', we rely on external partnerships such as this to provide sales and marketing for our nutraceuticals, which results in a mutually beneficial relationship."

"While nutraceuticals are a multibillion-dollar market, we at Therapeutic Solutions International pride ourselves on being 'science first'. Every product that we sell is backed by laboratory data, and in some cases clinical data," said Famela Ramos, Vice President of Business Development. "We are enthusiastic to enter relationships with specialized groups who are positioned to accelerate awareness of our natural and science-based catalogue of products."

"Our ability to distribute the revolutionary products of TSOI is a key element in protecting community health. Science is taking major strides in therapeutic technologies and their importance to immune system health. TSOI is an industry-leader in developing these technologies," said Steve Scholl, Principal of Community Shield LLC.

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

About Community Shield, LLC


Community Shield was founded on one principle: helping our community. Our goal is to continuously develop revolutionary ways to help our community cope with these uncertain times without fear of the unknown. The last thing you want is to feel unsafe navigating our new lifestyle – worried about getting sick or the large number of germs and bacteria now living on the various surfaces of your belongings and surroundings. Community Shield can help our communities shift to the "new normal."

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

https://www.therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer

Company Intensifies Basic Research Efforts on StemVacs Cancer Immunotherapy in Preparation for Responses to FDA Queries


https://www.prnewswire.com/news-release ... 23886.html


ELK CITY, Idaho, Feb. 8, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a new patent application with data demonstrating that mice immunized with StemVacs possesses a type of "memory" natural killer cells which are capable of transferring immunity to naïve mice. Typically, the concept of "immunological memory" applies only to cells of the adaptive immune system such as T cells and B cells, but not to natural killer cells, which are considered part of innate immunity.

In a series of experiments, mice bearing B16 melanoma were treated with StemVacs, which induced regression and eventual disappearance of the tumor. One month after disappearance of the tumor, mice were sacrificed, and NK cells were transferred to mice that were not treated with StemVacs. The mice receiving NK cells were resistant to development of melanoma upon challenge.

"This data completely contradicts the normal way in which immunology is perceived," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The possibility of inducing memory in natural killer cells using StemVacs suggests a very unique mechanism of action, which may imply potent efficacy as a monotherapy, as well as synergy with numerous immunotherapies currently in the clinic."

Although substantial survival in some patients has been achieved with immunotherapeutics called "checkpoint inhibitors", the majority of tumors do not respond because the tumors are considered "cold", meaning there is little immune recognition. The Company believes that StemVacs, by stimulating natural killer cells to attack cancer, may possess the ability to turn "cold" tumors into "hot", thereby making them susceptible to killing by the adaptive immune system.

"We are constantly exploring partnerships with companies in the area of cancer immunotherapy," said Famela Ramos, Vice President of Business Development. "This new data provides potent ammunition for business development activities due to the fact that to our knowledge, we are the first to use a dendritic cell based approach (StemVacs) to successfully induce what appears to be NK immunological memory."

"Currently we have filed a patent and are working diligently to identify the biological basis for stimulation of these potent NK cells, whose activity persisted for at least one month after clearance of the tumor," said Timothy Dixon, President and CEO of the Company. "Given the optimism associated with NK based companies such as Fate Therapeutics (market cap $9.6 billion) and Nantkwest (market cap $2.5 billion), we are excited to develop a novel way of stimulating these cells in the patient, as opposed to administering artificially created exogenous cells."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease

Clinical Stage Immunotherapy Company Aims to Initiate Phase III Clinical Trial to Register Life-Saving Universal Donor Lung Protecting Therapy


https://www.prnewswire.com/news-release ... 25932.html


ELK CITY, Idaho, Feb. 10, 2021/PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today acquisition of the JadiCell™, cell therapy, for use in the treatment of acute respiratory distress syndrome and other lung pathologies.

"Having worked with the Team at Therapeutic Solutions International for over 4 years, I am glad to place our highly promising and clinically advanced stem cell therapy into this innovative and cutting-edge company," said Dr. Amit Patel, inventor of the JadiCell. "Therapeutic Solutions International is unique in that it is currently running clinical trials in the area of nutraceuticals, as well as developing preclinical and clinical stage immunotherapies. There are numerous synergies to be had with the existing work and expertise in the Company."

"While there is a lot of excitement about various approaches to lung inflammation, there are very few therapies that not only potently block pathological immunity while concurrently induce regeneration of pulmonary tissues," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To date, by far the most promising regenerative therapy our scientists have worked with for acute respiratory distress syndrome (ARDS) has been the JadiCell. I am honored to work with our team of experts such as Dr. Francesco Marincola and Dr. Santosh Kesari in leading the JadiCell through Phase III and into the hands of patients."

"It is a significant accomplishment to acquire rights to this extremely promising and cost-effective technology that is scalable and functions as a 'cellular drug,'" said Famela Ramos, Vice President of Business Development. "To our knowledge this is the only stem cell therapy for lung pathologies that does not require animal components and can be generated in sufficient quantities to address the multi-billion-dollar market of ARDS."

"Dr. Patel and his team have been strong collaborators with us since our first licensing deal using the JadiCell for Chronic Traumatic Encephalopathy," stated Timothy Dixon, President and CEO of the Company. "Having worked with these cells, we appreciate that to date they are by far the most effective at production of cytokines, stimulation of regeneration, and inhibition of pathological inflammation. We are extremely confident in our ability to take these cells to the finish line in treatment of end stage lung disease."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board

Developer of First Tumor Vaccine to Receive Regulatory Approval Recruited to Accelerate Clinical Translation of StemVacs Cellular Immunotherapy


https://www.prnewswire.com/news-release ... 28899.html


ELK CITY, Idaho, Feb. 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today appointment of Dr. Boris Minev to the Scientific Advisory Board of the Company. Dr. Minev joins other internationally renowned tumor immunologists including Dr. Francesco Marincola, Dr. Santosh Kesari, and Dr. Feng Lin.

Dr. Boris Minev is currently the President of Medical and Scientific Affairs at Calidi Biotherapeutics, Inc. in San Diego, CA. Dr. Minev has a stellar track record of successes in the area of cancer immunotherapy, being a developer of Melacine® the first tumor vaccine to obtain regulatory approval. He held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology. Dr. Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy, for more than 15 years. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.

"I am proud to be invited by my long-term collaborator and friend Dr. Thomas Ichim to join the advisory board of Therapeutic Solutions International," said Dr. Minev. "Dr. Ichim and I previously accelerated translation of a novel cellular therapy from bench to bedside, which resulted in a stellar return for the investors of Medistem as a result of being acquired by Intrexon1. It is a great feeling to have the team together, including Dr. Feng Lin and Dr. Amit Patel who worked together with myself and Dr. Ichim at Medistem."

Last week the Company acquired the rights to Dr. Amit Patel's JadiCellsä for treatment of lung injuries2. These cells have previously been demonstrated to be safe and possess efficacy signals in a double-blind placebo controlled clinical trial in lung disease patients3.

"I look forward to working with Dr. Minev who is a pillar of the San Diego medical community when it comes to immuno-oncology research and practice," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "Many of my colleagues have read Dr. Minev's book, Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures…interestingly, our Vice President of Business Development, Famela Ramos, actually has a chapter written in that textbook."

"Dr. Minev is not only a brilliant tumor immunologist, but also his mind is completely obsessed with finding practical solutions to cancer treatment," said Timothy Dixon, President and CEO of the Company and co-inventor of StemVacs. "Working with someone who has both practical experiences as an MD, as well as deep theoretical knowledge obtained from training with Dr. Steven Rosenberg, strongly positions the Company to advanced StemVacs through the FDA regulatory process. We are very blessed to have Dr. Minev join us," added Mr. Dixon.

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Intrexon Completes Acquisition of Medistem (prnewswire.com)

2 Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease (prnewswire.com)

3 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - - STEM CELLS Translational Medicine - Wiley Online Library

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction

Company uses Blood Based Immune Test as "Stethoscope for the Brain"

"Suicide is a Disease, Not a Choice"


https://www.prnewswire.com/news-release ... 30996.html


ELK CITY, Idaho, Feb. 18, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today its spin-off company, Campbell Neurosciences Inc, successfully completed a 30-patient clinical trial assessing blood levels of an inflammatory cytokine as a predictor for suicidal ideation.

The clinical trial, which is registered on the Federal Clinical Trials website (#NCT04606875)1, assessed levels of inflammatory marker in 10 patients with no history of suicide (Group 1), 10 patients with suicidal ideations (Group 2), and 10 patients with suicidal ideations who attempted suicide in the last 6 months (Group 3). Results demonstrated that patients in Group 1 had 7.6±2.4 pg/ml of cytokine, whereas Group 2 had 28.9 ±6.3 pg/ml and in Group 3 had 45.8 ±7.7 pg/ml.

"This is the first step in the important journey to develop the first blood-based test for suicidal ideation" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The Campbell Score is named after my mother, Kathleen Campbell, who was a victim of suicide. These data support our original purpose for starting the Company, which is to prove that suicide is a disease and not a choice."

"The current data fits well into the paradigm that many mental illnesses possess an inflammatory component" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Miss O'Connor did an excellent job of summarizing existing clinical data supporting the association between inflammation and mental diseases in a pre-publication paper titled "Suicide: An Immunological Disorder?2" added Dr. Veltmeyer"

"By establishing a blood-based test, the Company aims to provide a new weapon for psychiatrists to use in their war against the second largest killer of young people between 15 to 34 years of age" said Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "As the parent company of Campbell Neurosciences, we have started discussions with various stakeholders in the mental health space with the idea of initiating wide-scale implementation of the Campbell Score."

"The interplay between the immune system and the brain has been known for a while but not acted upon in any significant manner until now" said Timothy Dixon, President and CEO of Therapeutic Solutions International. "As an immunotherapy company, we are proud at this initial success of our phase 2 clinical trial, because it preliminarily validates what we have been thinking all along: that the immune system can be used as a stethoscope for what is happening in the brain."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Correlation of Campbell Score With Suicidal Ideation - Full Text View - ClinicalTrials.gov

2 Suicide: An Immunological Disorder?

ir@tsoimail.com

SOURCE Therapeutic Solutions International, Inc.
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells

Novel Approach Leverages Existing Findings to Create "Killer T Cells" for Targeting "Root" of Cancer

https://www.prnewswire.com/news-release ... 32543.html


ELK CITY, Idaho, Feb. 22, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today novel data and filing of a patent application demonstrating that StemVacs™ cells carrying proprietary sequences from the cancer-specific antigen Brother of the Regulator of Imprinted Sites (BORIS), were able to elicit the generation of T cells capable of selectively killing cancer stem cells.

In contrast to other markers associated with cancer, BORIS is not simply a "flag" that is recognized by the immune system, but it is essential for cancer to be cancer. Dr. Thomas Ichim, Board Member of the Company, published that gene silencing of BORIS resulted in the death of cancer cells.1 National Institutes of Health Scientist Dr. Dmitri Loukinov, as well as other collaborators, published with Dr. Ichim that DNA immunization with BORIS resulted in suppression of aggressive breast cancer,2 as well as induction of T cells capable of killing glioma, leukemia, and mastocytoma.3

"Despite living in what is called the Golden Age of Immunotherapy, the majority of cancers still do not undergo substantial responses to current treatments," said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent application. "What is impressive about the StemVacs™ approach is that it can generate personalized T cells that selectively seek and destroy cancer stem cells. It is the cancer stem cells that are the 'roots' of the cancer. They are resistant to chemotherapy and radiotherapy and to my knowledge the only possible way of eliminating cancer stem cells is through immunotherapy."

"Having worked in the area of cellular therapy and vaccine development, the possibility of using an allogeneic dendritic cell-based approach to ex vivo generate cancer stem cell killing T effector cells is tantalizing," said Feng Lin, MD, Ph.D., Chief Scientific Officer of the Company. "I look forward to continuation of these studies and eventual clinical utilization."

Researchers believe current cancer treatments sometimes fail because they don't destroy the cancer stem cells. Think of cancer as a weed: the stem cells are the root while the remaining majority of the cells are the part of the weed above ground. If you remove only the leaves but not the root, the weed will grow back. The same is true for cancer: if you do not kill the cancer stem cells, the cancer is likely to return.4

"Cellular therapy is the future of medicine," said Famela Ramos, Vice President of Business Development of the Company and co-inventor of the patent. "This demonstration that StemVacs™ can generate "patient specific" killer cells that can be reinfused in patients offers a new area of product development for us, as well as an ability to implement a two-punch attack on the tumor."

"At Therapeutic Solutions International we are focused on researching, patenting, and implementing the most innovative and potentially effective immunotherapies we can develop," said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "The ability to generate tailor-made killer T cells that appear to selectively target cancer stem cells provides yet another complementary cellular immunotherapy in our growing armamentarium against this terrible disease."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

1 Selective apoptosis of breast cancer cells by siRNA targeting of BORIS - PubMed (nih.gov)
2 DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice (nih.gov)
3 Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites | The Journal of Immunology (jimmunol.org)
4 Cancer Stem Cell Research | University of Michigan Rogel Cancer Center

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
Post Reply